The FDA's September 10, 2025 draft guidance on non-opioid analgesic development marks a pivotal moment for pharmaceutical manufacturers, supplement companies, and the broader landscape of pain management therapeutics. This regulatory initiative doesn't merely offer recommendations—it establishes new pathways that will reshape how companies approach product development, clinical trials, and quality management systems in the chronic […]